Daridorexant Market

The Daridorexant market is expected to grow at a CAGR of 6.8% between 2025 and 2035, owing to the increased prevalence of chronic insomnia and the growing demand for dual orexin receptor antagonists (DORAs) as safer alternatives to existing sedative-hypnotic drugs.  Daridorexant, which is licensed for the treatment of insomnia caused by difficulties with sleep onset and/or maintenance, has little next-morning residual effects, distinguishing it in the CNS therapies landscape. Daridorexant, as an orexin receptor antagonist, provides a non-sedative, sleep-normalizing mechanism that reduces the dangers of reliance and cognitive impairment, which are major side effects of benzodiazepines and z-drugs.

Geographically, North America holds the largest share of the Daridorexant market, led by strong FDA support, rising insomnia diagnosis rates, and widespread awareness of DORAs among healthcare providers. Europe is witnessing consistent growth due to EMA approvals and increasing interest in insomnia-related research, especially in the elderly population. The Asia-Pacific region is emerging rapidly due to rising stress-related sleep disorders, expanding urban lifestyles, and increased mental health awareness. Japan, in particular, is a key market given its historically high prevalence of sleep disturbances. Latin America and the Middle East & Africa are gradually opening up through generic pathways and mental health advocacy initiatives.

The Daridorexant market is evolving with collaborations between specialty API manufacturers, neuro pharmaceutical companies, and clinical trial networks. Manufacturers are emphasizing chiral purity, particle size control, and polymorphic form selection to meet stringent regulatory and performance criteria. Moreover, the push for low-residual solvent synthesis and supply chain efficiency is fostering sustainable production practices. The rise in telemedicine, mental wellness platforms, and patient-centric formulations is expected to bolster the downstream demand, cementing Daridorexant’s place as a frontline agent in the modern insomnia therapy landscape.